Clinical candidates finding

The race to find nicotinic analgesics has - in a very few years - resulted in a cornucopia of potential clinical candidates. The following scheme is intended to give an overview of the most striking examples ... 

Target-Based Drug Discovery or Finding Clinical Candidates... 

Target-Based Drug Discovers or Finding Clinical Candidates in an AcademicSettingand What to Do When You ve Found One... 

A more recently synthesized derivative, 3,4 -dideoxy-OMT (MC-352 or YM-17K) was found to exhibit in vitro activity that compared favourably with commercially available macrolides [124-126]. The strong in vitro potencies and broad spectrum of macrolides related to OMT and rosaramicin have fueled many efforts to find derivatives with suitable oral efficacy and favourable preclinical features. In addition, new fermentation-derived members of this group such as cirramycin F-1 and F-2, izenamicin, and M-119-a have been isolated [127-129]. However, no OMT-related macrolide has yet emerged as a successful clinical candidate. 

TRK-851 is a clinical candidate for an antitussive drug it has a novel, complex morphinan ring system. The development of TRK-851 was motivated by the finding that NTI, a selective 8 opioid receptor antagonist, showed antitussive effect. In this section we will describe the process of developing TRK-851, including the structure-activity relationship (SAR) studies on NTI derivatives and the difficulties encountered in overcoming a defect in the metabolism of a prototype clinical candidate, TRK-850. 

The resulting optimized lead (preclinical candidate), if it displays no toxicity in cell and animal models, becomes a clinical candidate. If this stands the tests of efficacy and safety in humans and overcomes marketing hurdles, a new drug entity will enter the treasure trove of pharmacy. The Box 2.1 will help to appreciate that activity is a necessary but not sufQcient quahty of medicines. There is, of course, no ideal drug in real world, but one has to find a relative optimum. 

This section introduces the fundamentals of drug discovery and development, summarizing the roles of certain scientists who work within fipcos. It surveys preclinical discovery and chemical development, where many chemists find work. It also introduces other development efforts that occur when a clinical candidate has been chosen or when the choice nears. These efforts include drug metabolism, radiochemistry, and radioimmimology, and they also employ organic and medicinal chemists. 

Only those syntheses merit development that offer patentable novelty as chemical processes and that furnish an important product. At the outset of development, and at its conclusion, the structure and properties of the final product are already known. It possesses the desired therapeutic effect in an animal model of the human disease and the potential to serve an existing market. Development efforts are not devoted to improving the biological profile of a clinical candidate by finding a successor or a back-up drug. 

This transition to development therefore calls only for applied chemical research from developers. It can mark a shutdown of the exploratory efforts that led to finding the clinical candidate. Chemical developers advance the chosen compovmd without seeking a pharmacologically superior substance... 

A quick examination of any issue of the Journal of Medicinal Chemistry would reveal one or more papers describing the development and use of pharmacophore models. Pharmacophore models rarely lead directly to clinical candidates because of the relative coarseness of the representation. They are very useful in finding alternative chemotypes that may have more attractive properties for optimisation. Pharmacophore modelling has always been particularly useful for membrane targets, for which direct structural information has been One example is the discovery of novel ligands for the endothelin A... 

---